Overview Neo-adjuvant Abiraterone Prostate Study Status: Completed Trial end date: 2021-01-19 Target enrollment: Participant gender: Summary The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy. Phase: Phase 2 Details Lead Sponsor: Cancer Trials IrelandCollaborator: Janssen, LPTreatments: Abiraterone AcetateMethylprednisoloneMethylprednisolone acetateMethylprednisolone HemisuccinatePrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphate